TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male; 12-65 years of age~* Subjects with severe hemophilia A~* Previously treated with factor VIII for a minimum of 150 exposure days~Exclusion Criteria:~* Inhibitors to FVIII (current evidence or history)~* Any other inherited or acquired bleeding disorder in addition to Hemophilia A~* Platelet count \< 100,000/mm3~* Creatinine \> 2x upper limit of normal or AST/ALT (aspartate aminotransferase/alanine aminotransferase) \> 5x upper limit of normal

- Gender: MALE
- Minimum Age: 12 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): On-demand treatment of BAY94-9027 at individual dose and number of infusions based upon location and severity of bleeds
- Arm 2 (Type: EXPERIMENTAL): Prophylaxis treatment of BAY94-9027; 2 infusions per week over 10 weeks followed by 2 infusions per week over 26 weeks in the main trial; and at least 1 day per week in the extension for at least 100 ED
- Arm 3 (Type: EXPERIMENTAL): Prophylaxis treatment of BAY94-9027; 2 infusions per week over 10 weeks followed by infusion every 5 days over 26 weeks in the main trial; and at least 1 day per week in the extension for at least 100 ED
- Arm 4 (Type: EXPERIMENTAL): Prophylaxis treatment of BAY94-9027; 2 infusions per week over 10 weeks followed by infusion every 7 days over 26 weeks in the main trial; and at least 1 day per week in the extension for at least 100 ED

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ketamine Improves Post-Thoracotomy Analgesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Consecutive patients scheduled for elective minimally invasive direct coronary artery bypass (MIDCAB) or for lung resection via anterolateral thoracotomy during a 6-month period (Sep 2001-March 2002)~Exclusion Criteria:~Exclusion criteria were:~* American Society of Anesthesiologists (ASA) physical class ≥3, Emergency operations,~* Q-wave myocardial infarct occurring during the previous 3 weeks, or poor left ventricular function (e.g., ejection fraction \[EF\] \<30% by echocardiography or angiography).~Other exclusion criteria were:~* A body mass index \>35 kg/m2,~* Past or current neuropathy or psychological disturbances,~* The use of centrally active drugs,~* Chronic liver or renal failure requiring dialysis,~* A FEV1/FVC \<70%,~* Allergy to ketamine, morphine or non steroidal anti inflammatory drugs (NSAIDs),~* Clotting abnormalities,~* A platelets count \<70000/mm3,~* A white blood count \<3000\>14000/mm3,~* Uncontrolled diabetes mellitus or fasting blood glucose \>250 g/dl,~* Evidence of sepsis or infection up to one week prior to randomization.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- morphine only (Type: ACTIVE_COMPARATOR): standard analgesia protocol
- morphine ketamine (Type: EXPERIMENTAL): alterantive regimen for intravenous patient controlled analgesia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Effects of Intermittent Hypoxia on Restoring Hand Function Following SCI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 18 and 65 years~* medical clearance to participate~* lesion below the 5th cervical spinous process (C5) and above the first thoracic spinous process (T1) with non-progressive etiology~* classified as motor-incomplete injury greater than 12 months~* independent breathing~Exclusion Criteria:~* Concurrent severe medical illness (i.e., infection, cardiovascular disease, ossification, recurrent autonomic dysreflexia, unhealed decubiti, and history of cardiac or pulmonary complications)~* Pregnant women because of the unknown affects of acute intermittent hypoxia on pregnant women and fetus~* Concomitant acquired brain injury~* History of seizures, brain injury, and/or epilepsy~* Diagnosed with obstructive sleep apnea~* Undergoing concurrent physical therapy~* Any contraindications to EMG testing procedures (skin sensitivity)~* Any contraindications to passive movement of the limbs~* Score of \< 24 on Mini-Mental Exam

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- AIH/Sham (Type: ACTIVE_COMPARATOR): Subjects with chronic, motor-incomplete SCI receive AIH and then SHAM
- Sham/AIH (Type: ACTIVE_COMPARATOR): Subjects with chronic, motor-incomplete SCI receive SHAM and then AIH

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Blood Levels of Fatty Acids After Consuming Two Forms of Cod Liver Oil

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteers aged 18 to 45 years (both inclusive)~* Body mass index (BMI) of 18.5-29.9 kg/m2 inclusive~Exclusion Criteria:~* Pregnant or lactating women~* Allergy/intolerance to any study material~* Current or recurrent disease, within 12 months of screening that could affect the metabolism of drug~* Participants who have taken any drug known to induce or inhibit hepatic drug metabolism in 30 days prior to screening~* Positive serum Hepatitis B surface antigen, Hepatitis C antibodies or Human Immunodeficiency Virus (HIV), alcohol or drug abuse~* Smokers taking \>5 cigarettes/day; prior or current use of any other nicotine containing product~* Blood donated within 3 months of screening~* Consumed n-3 rich food or beverage or n-3 fortified food or beverage within 72h prior to each study session

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Test (Type: EXPERIMENTAL): 30mL Test contains 10%w/w cod oil + 10%w/w cod liver oil in an emulsion formulation
- Control (Type: ACTIVE_COMPARATOR): 5.8mL of cod liver oil in a free flowing non-emulsified formulation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Apixaban for the Prevention of Venous Thromboembolism in Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A newly diagnosed cancer site or progression of the malignant disease after complete or partial remission.~* Initiating a new course of chemotherapy with a minimum intent of 3 months therapy~* A VTE risk stratification score of ≥ 2, according to the scoring method~* Age 18 years old or older~* Provide written informed consent~Exclusion Criteria:~* Lesions or conditions at increased risk of clinically significant bleeding (eg. active peptic ulcer disease)~* Objectively confirmed substantial liver insufficiency as defined by clinical manifestations of ascites, cirrhosis, encephalopathy and/or jaundice and/or biochemical abnormalities in liver function tests including hypoalbuminemia (\< 3.5 gr/dL), elevated levels of total bilirubin (\> 25 umol/L), elevated liver transaminases (2 times the upper limit of normal) and/or biochemical diagnosis of biliary tract obstruction (elevated levels of gamma-glutamyl transferase and alkaline phosphatase, 3 times the upper limit of normal). \*~* Diagnosis of basal cell or squamous cell carcinoma of the skin or acute leukemia or myelodysplastic syndrome\*\*~* Planned stem cell transplant~* Life expectancy less than 6 months~* Acute or chronic renal insufficiency with glomerular filtration rate (GFR) \< 30 ml/min calculated by the Cockroft and Gault formula.~* Pregnancy\*\*\*~* Continuous anticoagulation with vitamin K antagonists, low-molecular-weight heparin (LMWH), or other oral anticoagulants~* Weight \< 40 Kg~* Platelet count \< 50 x 109/L~* Known allergies to ingredients contained in apixaban~* Use of any contraindicated medications with apixaban

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Apixaban (Type: ACTIVE_COMPARATOR): 2.5 mg BID for 6 months
- Placebo drug (Type: PLACEBO_COMPARATOR): 2.5 mg BID for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Obesity as a consequence of acquired anatomical hypothalamic damage as evidenced by BMI ≥30 and ≤60 kg/m2~* Greater than 6 months post-treatment, including chemotherapy, surgery or radiation with resulting injury to the hypothalamus and/or the pituitary~* Stable body weight for at least 3 months~* Type 2 diabetes mellitus is allowed~Exclusion Criteria:~* Males taking gonadotropin replacement therapy (LH/FSH)~* Subjects who are planning any fertility treatment within 6 months of study participation~* Use of weight loss agents, including herbal medications, in the past 3 months~* Current or anticipated chronic use of narcotics or opiates~* History of severe psychiatric disorders~* Type 1 diabetes mellitus~* Metabolic disorders or genetic disorders linked to obesity~* History of any bariatric surgery~* Participation in any clinical study with an investigational drug or device within the 3 months prior to enrollment in this study~* Blood loss or donation \>500 mL within the past 3 months~* Females who are pregnant, nursing, intend to become pregnant during the study or any males who plan to father/conceive a child within 6 months after completion of study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- ZGN-440 sterile diluent (Type: PLACEBO_COMPARATOR): Subjects will receive placebo twice weekly subcutaneous injections for 4 weeks.
- ZGN-440 for injectable suspension (Type: EXPERIMENTAL): Subjects will receive ZGN-440 for injectable suspension (beloranib) twice weekly subcutaneous injections for up to 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Varied Outreach Methods on Appointment Scheduling, Appointment Completion, and Receipt of MMR Vaccination

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 12-14 months old OR 4 years old~* Has not yet received first MMR (for 12-14 month olds) OR second MMR (for 4 year olds)~* Has not had a well child check in past 365 days (for 4 year olds)~* No appointment scheduled in the next 45 days~* Parent preferred language = English or Spanish~Exclusion Criteria:~* Phone number not available in electronic medical record

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 4 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None
- Arm 2 (Type: EXPERIMENTAL): None
- Arm 3 (Type: EXPERIMENTAL): None
- Arm 4 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Traumatic Brain Injury and Risk for Chronic Traumatic Encephalopathy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Agreement to participate in study;~2. A history of TBI resulting from, but not limited to, any of the following: contact sports, accidents, violence, or military combat;~3. Age 18 or older;~4. No significant cerebrovascular disease;~5. Adequate visual and auditory acuity to allow neuropsychological testing;~6. Screening laboratory tests without significant abnormalities that might interfere with the study.~Exclusion Criteria:~1. Preexisting major neurological or other physical illness that could confound results (e.g., multiple sclerosis, diabetes, cancer);~2. History of myocardial infarction within the previous year or unstable cardiac disease.~3. Uncontrolled hypertension (systolic blood pressure \> 170 or diastolic blood pressure \> 100),~4. History of significant liver disease, clinically significant pulmonary disease, diabetes, or cancer.~5. Such current major psychiatric disorders as mania within the previous two years.~6. Participants taking drugs that are known to affect \[F-18\]FDDNP-PET binding (e.g., ibuprofen, naproxen) were asked to stop taking medication one week prior to PET scan or excluded from the study.~7. Use of any investigational drugs within the previous month, depending on drug half-life.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Suspected CTE (Type: None): A total of 22 participants with suspected CTE were studied. Each received clinical and neuropsychological assessments, \[F-18\]FDDNP-PET scans, and magnetic resonance imaging (MRI) scans, or computed tomography scans if they could not tolerate MRI (to assist in PET region of interest identification).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Eligibility Criteria:~* Active rheumatoid arthritis currently failing anti-TNF therapy or have failed anti-TNF therapy in the past.~Exclusion Criteria:~* Women who are pregnant or breast feeding~* Current symptoms of serious medical disease~* History of cancer in last 5 years other than non-melanoma skin cancer~* Chronic serious infection~* Active TB requiring treatment in last 5 years~* Herpes zoster in last 2 months~* Any active viral infection including Human Immunodeficiency Virus (HIV)~* Serious side effects associated with previous anti-TNF therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Abatacept (Type: ACTIVE_COMPARATOR): Short Term Portion of Study
- Placebo (Type: PLACEBO_COMPARATOR): Short Term Portion of Study
- Abatacept (Long Term) (Type: ACTIVE_COMPARATOR): Long Term Portion of Study:~All participants receive Active Drug

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Double-blind, Randomized, Parallel Design Study to Compare the Effectiveness of Sugammadex Versus Neostigmine in Improving Surgical Condition in Subjects Undergoing Laryngeal Microsurgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients of age over 20 years~* scheduled for laryngeal microsurgery under general anesthesia~Exclusion Criteria:~* anticipated difficult intubation, cervical spine disease, neuromuscular disease, acute or chronic renal failure, liver cirrhosis or liver failure~* history of allergy to nondepolarizing muscle relaxant~* history of malignant hyperthermia~* pregnant woman~* body mass index over 35 kg/m2

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Neostigmine arm (Type: EXPERIMENTAL): Neostigmine arm
- Sugammadex arm (Type: ACTIVE_COMPARATOR): Sugammadex arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has type 2 diabetes mellitus~* Is currently not on an anti-hypoglycemic agent (AHA) (off for at least 12 weeks) and has a Visit 1/Screening Visit HbA1c greater than or equal to 7.0% and less than or equal to 9.5%; or is currently on AHA monotherapy or low-dose oral combination therapy (i.e., less than or equal to 50% maximum labeled dose of each agent) and has a Visit 1/Screening Visit HbA1c greater than or equal to 6.5% and less than or equal to 9.0%~Exclusion Criteria:~* Has a history of type 1 diabetes mellitus or a history of ketoacidosis~* Has been on any investigational or approved glucagon-like peptide-1 (GLP-1) analogue (such as exenatide, liraglutide, etc.), any investigational or approved dipeptidyl peptidase IV (DPP-4) inhibitor (such as sitagliptin, vildagliptin, alogliptin, etc.) or a peroxisome proliferator-activated receptor (PPAR) gamma agonist agent (such as rosiglitazone, pioglitazone, etc.) within 12 weeks of Visit 1~* Required insulin within the prior 12 weeks~* Has a hypersensitivity or contraindication to any sulfonylurea medication (such as glimepiride, glipizide, etc.), DPP-4 inhibitor (such as sitagliptin, vildagliptin, alogliptin, etc.), or biguanide medication (such as metformin, etc.)~* Has inadequately controlled hypertension~* Has cirrhosis or active liver disease~* Has severe cardiac conditions~* Is obese~* Has human immunodeficiency virus (HIV)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sitagliptin/Metformin FDC (Type: EXPERIMENTAL): Participants in the Sitagliptin/Metformin Fixed- Dose Combination (Sita/Met FDC) group received tablets of Sita/Met FDC and placebo tablets matching glimepiride for 30 weeks. The dose for Sita/Met FDC was 50/500 mg twice daily (b.i.d.) starting Day 1 and increased to 50/1000 mg b.i.d. over a period of 4 weeks.
- Glimepiride (Type: ACTIVE_COMPARATOR): Participants in the Glimepiride group received 2 placebo tablets matching Sita/Met FDC and glimepiride tablets (1 mg or 2 mg) for 30 weeks. The dose for glimepiride was 1 mg once daily (q.d.) starting Day 1 and up-titrated as considered appropriate by the investigator based upon the results of participant's self-monitored blood glucose levels but not to exceed 6 mg/day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: DILIPO (DILutIonal HyPOnatremia)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or Female patients aged 18 higher~* Dilutional Hyponatremia with serum sodium between 115 and 132 mmol/L~* Ability to give written informed consent (the informed consent may be signed by a legally authorized representative if the patient is unable to sign)~Exclusion Criteria:~* Presence of known or untreated adrenal insufficiency, SIADH or cirrhosis, or hyperthyroidism~* Presence of signs of hypovolemia~* Administration of other V2 receptor antagonists or demeclocycline or lithium within one month and urea within two days prior to study drug administration~* Presence of uncontrolled diabetes with fasting glycemia ³ 200 mg/dL (³ 11.09 mmol/L)~* Patients considered by the Investigator unsuitable candidates to receive an investigational drug (e.g., presence of any neurological symptoms that may worsen in five days, based on the judgment of the Investigator, or presence of any neurological symptoms for which the persistence of hyponatremia over several days may be deleterious)~* Administration of inducers of CYP3A4 (phenobarbital, phenytoin, rifampin, Saint John's Wort) or potent and moderate inhibitors of CYP3A4 within two weeks prior to study drug administration~* Presence or history of allergic reaction to SR121463B8~* Previous study with SR121463B~* Inadequate hematological, renal, and hepatic functions: hemoglobin (Hb) \< 9 g/dL, neutrophils \< 1,500/mm3, platelets \< 100,000/mm3, serum creatinine \> 175 mol/L (or clearance of creatinine \< 30 mL/min for sites where Ethics Committees require this parameter), serum alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) \> 2 x upper limit of normal (ULN)~* QTCB 500 ³ ms~* Positive pregnancy test and absence of medically approved contraceptive methods (e.g., surgical sterilization of more than one month duration, oral contraception or intrauterine device in combination with either diaphragm, condom, or spermicide) for females of childbearing potential~* Pregnancy or breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete